ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19
article controlled clinical trial controlled study coronavirus disease 2019 cytokine storm drug safety exosome gene therapy human human cell mesenchymal stroma cell preclinical study quality control
; 2020(Cytotherapy): PMC7229942,
Article
in English
| May 16 | ID: covidwho-643133
ABSTRACT
STATEMENT The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.
Search on Google
Collection:
Databases of international organizations
Database:
May 16
Type of study:
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
Article controlled clinical trial controlled study coronavirus disease 2019 cytokine storm drug safety exosome gene therapy human human cell mesenchymal stroma cell preclinical study quality control
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS